Internal Reference Number: FOI_9547
Date Request Received: 14/07/2026 00:00:00
Date Request Replied To: 31/07/2026 00:00:00
This response was sent via: By Email
Request Summary: Treatment of Ovarian Cancer
Request Category: Private Individuals
| Question Number 1: How many patients have been treated for advanced (FIGO Stages III and IV) ovarian (epithelial ovarian, fallopian tube or primary peritoneal) cancer over the last 3 months? If none, do you refer advanced ovarian cancer patients to another trust, and if so which one? | |
| Answer To Question 1: 25 (from Aria data) | |
| Question Number 2: How many ovarian cancer patients (any stage) have been treated in the last 3 months with: Paclitaxel in combination with a platinum-based compound Platinum-based therapy alone (cisplatin or carboplatin) Bevacizumab in combination with paclitaxel and carboplatin Olaparib Olaparib + Bevacizumab Niraparib Rucaparib Mirvetuximab soravtansine | |
| Answer To Question 2: Paclitaxel in combination with a platinum-based compound 6 Platinum-based therapy alone (cisplatin or carboplatin) less than 5 Bevacizumab in combination with paclitaxel and carboplatin 5 Olaparib less than 5 Olaparib + Bevacizumab 0 Niraparib 5 Rucaparib less than 5 Mirvetuximab soravtansine 0 | |
| Question Number 3: Does your trust participate in any clinical trials for the treatment of ovarian cancer? If so, please provide the name of each trial along with the number of patients taking part. | |
| Answer To Question 3: SA国际传媒 is not currently participating in any clinical trials for the treatment of ovarian cancer. | |
| Question Number 4: If data for HRD (homologous recombination deficiency) testing is available, please provide how many HRD positive patients were treated in the last 3 months with: Olaparib Olaparib + Bevacizumab Niraparib Other treatments | |
| Answer To Question 4: Olaparibless than 5 Olaparib + Bevacizumab 0 Niraparib 0 Other treatments less than 5 | |
| To return to the list of all the FOI requests please click here |
Our staff at SA国际传媒 Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
